Mednax Inc

Pediatrix Medical Group reported second-quarter 2026 net revenues of $487.8 million, up 4% year over year, as acquisitions and higher same-unit pricing offset a 2.1% decline in same-unit revenues tied to patient volume. Same-unit revenues from net reimbursement-related factors rose 4% year over year, helped by improved revenue-cycle management cash collections, a favorable payor mix and higher patient acuity, primarily in neonatology, while commercial and other non-government payor mix improved 135 basis points from the year-ago period. Adjusted EBITDA increased to $76.4 million from $73.2 million, and the company reaffirmed its 2026 adjusted EBITDA outlook of $280-$300 million. Pediatrix expects full-year patient volumes to be roughly flat to slightly lower, and the benefit from stronger revenue-cycle collections is expected to ease in the second half of 2026, while higher salaries and malpractice expenses could weigh on operating leverage. Among peers, Tenet Healthcare posted a 6% year-over-year increase in hospital unit net operating revenues with admissions up 2.3%, and HCA Healthcare reported admissions up 2.4% with revenue per equivalent admission up 6%.

Pediatrix Medical Group reported second-quarter 2026 adjusted earnings per share of 63 cents, beating the Zacks Consensus Estimate by 10.5% and up 18.9% year over year, while net revenues rose 4.1% to $487.8 million, surpassing estimates by 2.2%. The company's performance was driven by improved cash collections and a favorable payor mix, partly offset by lower patient volumes and higher operating costs. Management reaffirmed its 2026 adjusted EBITDA guidance of $280-$300 million and raised its net income forecast to $147.6-$162.1 million. Shares have gained 3.4% since the earnings report, outperforming the S&P 500, and estimates have trended upward, though the stock carries a Zacks Rank #3 (Hold).

Pediatrix Medical Group reported second-quarter 2026 adjusted earnings per share of 63 cents, beating the Zacks Consensus Estimate by 10.5% and rising 18.9% year over year. Net revenues increased 4.1% to $487.8 million, surpassing estimates by 2.2%, driven by improved cash collection activity and a favorable payor mix, along with contributions from recent acquisitions, though partly offset by lower patient volumes and higher operating costs. Adjusted EBITDA rose 4.4% to $76.4 million, and the company reaffirmed its full-year 2026 adjusted EBITDA guidance of $280 million to $300 million. During the first half of 2026, Pediatrix repurchased 2.8 million shares for $61.7 million, with $104.5 million remaining under its buyback program as of June 30.